Pharmacokinetic Study and Optimal Formulation of New Anti-Parkinson Natural Compound Schisantherin A
Our recent studies showed that schisantherin A (StA) is a promising candidate for PD treatment, but the pharmacokinetic profile of StA is largely unknown. The effects of different formulations on the pharmacokinetics and bioavailability of StA were investigated by HPLC equipped with a vacuum degasse...
Main Authors: | Fei Sa, Bao Jian Guo, Sai Li, Zai Jun Zhang, Hok Man Chan, Ying Zheng, Simon Ming Yuen Lee |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Parkinson's Disease |
Online Access: | http://dx.doi.org/10.1155/2015/951361 |
Similar Items
-
Development of Schisantherin A and baicalein nano-formulations with improved oral bioavailability, brain uptake, and anti-Parkinsonian activity
by: Chen, Tong Kai
Published: (2017) -
Schisantherin A Attenuates Neuroinflammation in Activated Microglia: Role of Nrf2 Activation Through ERK Phosphorylation
by: Chuwen Li, et al.
Published: (2018-06-01) -
Protective role of deoxyschizandrin and schisantherin A against myocardial ischemia-reperfusion injury in rats.
by: Ruimiao Chang, et al.
Published: (2013-01-01) -
Pharmacokinetic study of new synthetic anti-tumor compound, CYL, and its SLN formulation
by: Hui-Lan Lin, et al.
Published: (2006) -
Investigation of the Impact of <i>CYP3A5</i> Polymorphism on Drug–Drug Interaction between Tacrolimus and Schisantherin A/Schisandrin A Based on Physiologically-Based Pharmacokinetic Modeling
by: Qingfeng He, et al.
Published: (2021-02-01)